Medical comorbidities of patients receiving amyloid‐targeting treatments in a memory clinic
William J. B. Powell, Suzanne E. Schindler, Martí Jiménez‐Mausbach, Inez Y. Oh, Anna Hofmann, Barbara Joy Snider, Madeline Paczynski, Nupur Ghoshal, Philip R. O. Payne, Albert M. Lai, Mackenzie R Hofford, Aditi GuptaAbstract
INTRODUCTION
Trials of amyloid‐targeting treatments (ATTs) for early symptomatic Alzheimer's disease (AD) enrolled selected patients with minimal medical comorbidities. We investigated whether real‐world memory clinic patients who received ATTs also had fewer comorbidities than the broader clinic population.
METHODS
We extracted data on demographics, comorbidities, and medications from patients who were seen at the Washington University Memory Diagnostic Center from July 1, 2023, through July 1, 2025. We compared the characteristics of patients by biomarker testing status and ATT treatment status.
RESULTS
Of 9938 unique patients, 1948 underwent AD biomarker testing and 335 received ATT infusions (304 lecanemab, 31 donanemab). The patients who underwent biomarker testing or received ATTs were more likely to be White individuals and to have fewer comorbidities than patients who did not undergo testing or receive ATTs.
DISCUSSION
Real‐world ATT patients were healthier than the general clinic population and more similar to clinical trial participants.